Literature DB >> 15288824

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children.

S K Obaro1, D Pugatch, K Luzuriaga.   

Abstract

Children infected by HIV-1 are particularly vulnerable to severe, recurrent, or unusual infections by vaccine-preventable pathogens. Routine immunisations seem to be generally safe for HIV-1-infected children, but responses may be suboptimal. Early HIV-1-induced immune attrition associated with viral replication may particularly interfere with the development of memory responses. In high HIV-1 prevalence regions, the accumulation of susceptible hosts may compromise disease-control efforts. Although early control of viral replication through treatment with highly active therapy may preserve immune function and responses to routine childhood vaccines, availability is limited in the areas most affected. In this review, we provide an overview of the immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. The possible immunological bases for defective responses are discussed; unanswered questions and the need for further research are delineated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288824     DOI: 10.1016/S1473-3099(04)01106-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  22 in total

1.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

Review 2.  Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries.

Authors:  Katayi Mwila; Roma Chilengi; Michelo Simuyandi; Sallie R Permar; Sylvia Becker-Dreps
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 3.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Authors:  Jorge Lujan-Zilbermann; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Mark J Abzug; Barb Heckman; Adam Manzella; Bill Kabat; Patrick Jean-Philippe; Sharon Nachman; George K Siberry
Journal:  J Pediatr       Date:  2012-05-22       Impact factor: 4.406

5.  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors:  George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

6.  Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Authors:  George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

7.  Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.

Authors:  Nishaki Mehta; Coleen K Cunningham; Patricia Flynn; Joyce Pepe; Stephen Obaro; Bill G Kapogiannis; James Bethel; Katherine Luzuriaga
Journal:  Vaccine       Date:  2010-03-28       Impact factor: 3.641

8.  Glycosylation, hypogammaglobulinemia, and resistance to viral infections.

Authors:  Mohammed A Sadat; Susan Moir; Tae-Wook Chun; Paolo Lusso; Gerardo Kaplan; Lynne Wolfe; Matthew J Memoli; Miao He; Hugo Vega; Leo J Y Kim; Yan Huang; Nadia Hussein; Elma Nievas; Raquel Mitchell; Mary Garofalo; Aaron Louie; Derek C Ireland; Claire Grunes; Raffaello Cimbro; Vyomesh Patel; Genevieve Holzapfel; Daniel Salahuddin; Tyler Bristol; David Adams; Beatriz E Marciano; Madhuri Hegde; Yuxing Li; Katherine R Calvo; Jennifer Stoddard; J Shawn Justement; Jerome Jacques; Debra A Long Priel; Danielle Murray; Peter Sun; Douglas B Kuhns; Cornelius F Boerkoel; John A Chiorini; Giovanni Di Pasquale; Daniela Verthelyi; Sergio D Rosenzweig
Journal:  N Engl J Med       Date:  2014-04-09       Impact factor: 91.245

9.  Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.

Authors:  Steven C Derrick; Teresa H Evering; Vasan K Sambandamurthy; Kripa V Jalapathy; Tsungda Hsu; Bing Chen; Mei Chen; Robert G Russell; Ana Paula Junqueira-Kipnis; Ian M Orme; Steven A Porcelli; William R Jacobs; Sheldon L Morris
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

10.  Vaccines to prevent pneumonia and improve child survival.

Authors:  Shabir A Madhi; Orin S Levine; Rana Hajjeh; Osman D Mansoor; Thomas Cherian
Journal:  Bull World Health Organ       Date:  2008-05       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.